January 31, 2022 Acad, Gov/Utilities

FDA approves Roche’s Vabysmo, the first bispecific antibody for the eye, to treat two leading causes of vision loss

Vabysmo (faricimab-svoa) targets and inhibits two disease pathways that drive neovascular or “wet” age-related macular degeneration (nAMD) and diabetic macular edema (DME) Vabysmo is the only injectable eye medicine approved simultaneously in the US for nAMD and DME, with flexible dosing regimens based on patient need Basel, 31 January 2022 – Roche (SIX: RO, ROG; OTCQX:... Read more

January 25, 2022 Acad, Gov/Utilities Licensing, IP, and Legal

Roche’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)

Interim data submitted to the FDA show majority of pre-symptomatic babies treated with Evrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowing Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated... Read more

January 24, 2022 Uncategorized

The Lancet publishes studies showing Roche’s faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Two papers in The Lancet highlight one-year results from Roche’s phase III trials evaluating faricimab in neovascular or “wet” age-related macular (nAMD) and diabetic macular edema (DME) Across four studies, about half of eligible faricimab patients were able to go four months between treatments, and approximately three-quarters could be treated every three months or longer... Read more